Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

6.60
+0.760013.01%
Post-market: 6.920.3200+4.85%19:53 EDT
Volume:147.08K
Turnover:901.07K
Market Cap:3.35M
PE:-0.06
High:6.70
Open:5.75
Low:5.54
Close:5.84
52wk High:3,840.00
52wk Low:5.25
Shares:507.40K
Float Shares:507.20K
Volume Ratio:4.08
T/O Rate:29.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-118.4105
EPS(LYR):-2,427.8177
ROE:-106.98%
ROA:-53.08%
PB:0.26
PE(LYR):0.00

Loading ...

Clearmind Medicine Issues Press Release Update

Reuters
·
Jul 07

Clearmind Medicine Wins New US Patent for Binge Behavior Regulators

Reuters
·
Jun 29

Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

Reuters
·
Jun 22

Clearmind Medicine - to Initiate Next Stage of Clinical Program for Alcohol Use Disorder

THOMSON REUTERS
·
Jun 22

Clearmind Medicine Reaches Major Milestone, Completing Part a Treatment in FDA‑Regulated Phase I/Ii Trial

THOMSON REUTERS
·
Jun 22

HRT Financial LP disposes of $73,191 in Clearmind Medicine common shares

Reuters
·
Jun 19

Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial

TIPRANKS
·
Jun 18

Clearmind Medicine wins US patent for MEAI-based binge behavior regulators

Reuters
·
Jun 18

HRT Financial LP sells 3,183 Clearmind Medicine common shares for $10,567.56

Reuters
·
Jun 18

HRT Financial LP disposes of 2,102 Clearmind Medicine common shares worth $7,062.72

Reuters
·
Jun 16

BRIEF-Clearmind Medicine Completes Dosing For Part A Of Its Of FDA-Regulated Phase I/Ii Clinical Trial

Reuters
·
Jun 16

Clearmind Medicine Completes Dosing in First 4 Cohorts of Phase I/II Alcohol Use Disorder Trial

MT Newswires Live
·
Jun 16

Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

Reuters
·
Jun 16

Clearmind Medicine Completes Dosing for Part a of Its of FDA-Regulated Phase I/Ii Clinical Trial

THOMSON REUTERS
·
Jun 16

Clearmind Medicine says HRT Financial files initial beneficial ownership statement

Reuters
·
Jun 13

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM

Reuters
·
Jun 08

Clearmind Medicine spotlights new CMND-100 alcohol use disorder trial data in June 10 webinar

Reuters
·
Jun 05

Clearmind Medicine to Feature New Insights From Cmnd-100 Psychedelic Clinical Trial on “Inside Meai” Webinar

THOMSON REUTERS
·
Jun 05

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

GlobeNewswire
·
Jun 05

Clearmind Medicine to sell $1.5 million in convertible promissory notes at 90% of face value

Reuters
·
Jun 02